Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company’s recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Cautious Outlook on Recursion Pharmaceuticals Amid Strategic Restructuring and Cash Management Challenges
- Largest borrow rate increases among liquid names
- Recursion Pharmaceuticals Announces Workforce Reduction Strategy
- Recursion Pharmaceuticals announces 20% workforce reduction
- Unusually active option classes on open June 9th